Zimmer Biomet stock (US98956P1021): Leading medical device maker with strong US market presence

Zimmer Biomet, a key player in orthopedic implants and medical devices, continues to serve the growing US demand for joint replacements and surgical solutions amid an aging population.

Zimmer Biomet focuses on orthopedic reconstructive products, sports medicine, biologics, extremities, trauma, spine, dental, and bone cement technologies. The company reported full-year 2025 revenue of $7.6 billion in its Q4 and full-year results published February 6, 2026, up 6.4% on a reported basis and 7.6% adjusted from the prior year, driven by strong US performance.

The stock traded at $102.35 USD on May 14, 2026 on NYSE, according to Yahoo Finance as of 05/14/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zimmer Biomet Holdings, Inc.
• Sector/industry: Healthcare / Medical Devices
• Headquarters/country: Warsaw, Indiana, USA
• Core markets: US, Europe, Asia-Pacific
• Key revenue drivers: Orthopedic implants, knees, hips
• Home exchange/listing venue: NYSE (ZBH)
• Trading currency: USD

Zimmer Biomet: core business model

Zimmer Biomet develops, manufactures and markets orthopedic reconstructive products for knees, hips, shoulders, extremities and trauma, as well as sports medicine, biologics, spine and dental products. The company serves surgeons and patients globally, with a strong emphasis on innovation in implant technology and surgical tools. Headquartered in Warsaw, Indiana, it operates in over 25 countries.

Innovation drives the model, with R&D investments supporting robotic-assisted surgery systems like ROSA and the Persona IQ smart knee implant. These technologies aim to improve surgical precision and patient outcomes, positioning Zimmer Biomet as a leader in personalized orthopedics.

Main revenue and product drivers for Zimmer Biomet

Orthopedics reconstructive products account for the majority of revenue, with knees at 37%, hips 28%, and other reconstructive 11% of 2025 full-year sales per the February 6, 2026 earnings release on the company website. US sales represented 57% of total revenue in that period, highlighting strong domestic demand.

Sports medicine, biologics and extremities contribute additional growth, while international markets provide diversification. Key products include the Oxford Partial Knee and Persona Hip System, which have seen procedural growth in recent quarters.

Industry trends and competitive position

The global orthopedics market is projected to grow at 5-7% annually through 2030, fueled by aging populations and rising joint replacement procedures in the US, according to Statista as of 2026. Zimmer Biomet competes with Stryker, DePuy Synthes and Smith & Nephew.

Zimmer Biomet holds a leading position in knees and hips in the US, benefiting from its comprehensive portfolio and digital surgery tools. Its focus on outpatient procedures aligns with healthcare shifts toward cost efficiency.

Why Zimmer Biomet matters for US investors

As a NYSE-listed company with majority US revenue, Zimmer Biomet offers direct exposure to the world's largest orthopedics market. The US accounts for over half of procedures, driven by Medicare coverage and an aging baby boomer population.

Investors track its performance amid healthcare policy changes and reimbursement trends, which impact device adoption. The firm's innovation pipeline supports long-term relevance in American hospitals and surgery centers.

Conclusion

Zimmer Biomet maintains a solid position in the medical device sector, with recent financials showing revenue growth and US market strength. Ongoing innovation in robotics and smart implants supports its competitive edge. Market dynamics including demographic trends continue to shape its trajectory for US investors.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.